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The long-term survival of biomaterial implants is often hampered by surgery-induced
inflammation that can lead to graft failure. Considering that most corneas receiving grafts are
either pathological or inflamed before implantation, the risk of rejection is heightened. Here,
we show that bioengineered, fully synthetic, and robust corneal implants can be manu-
factured from a collagen analog (collagen-like peptide-polyethylene glycol hybrid, CLP-PEG)
and inflammation-suppressing polymeric 2-methacryloyloxyethyl phosphorylcholine (MPC)
when stabilized with the triazine-based crosslinker 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride. The resulting CLP-PEG-MPC implants led to reduced corneal
swelling, haze, and neovascularization in comparison to CLP-PEG only implants when grafted
into a mini-pig cornea alkali burn model of inflammation over 12 months. Implants incor-
porating MPC allowed for faster nerve regeneration and recovery of corneal sensation. CLP-
PEG-MPC implants appear to be at a more advanced stage of regeneration than the CLP-PEG
only implants, as evidenced by the presence of higher amounts of cornea-specific type V
collagen, and a corresponding decrease in the presence of extracellular vesicles and exo-
somes in the corneal stroma, in keeping with the amounts present in healthy, unoperated
corneas.
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B iomaterial implants, like organ transplants, suffer inflam-mation that can result in immune rejection and graftfailure.1 This is a consideration when developing corneal
implants for treating patients not amenable to conventional
human donor transplantation.
Globally, approximately 23 million people have unilateral cor-
neal blindness and 4.6 million are bilaterally blind.2 For the past
century, the only widely accepted treatment for corneal blindness
has been human donor corneal transplantation. First-time, low-
risk grafts are over 90% successful for the first 2 years post-
operation.3 However, this declines to 55% by 15 years due to
chronic inflammation.4 A severe worldwide human donor cornea
shortage leaves 12.7 million patients awaiting transplantation, with
only one in 70 patients being treated.5 Patients with inflammation
and severe pathologies have risks of up to 70% for rejecting donor
allografts.3 So, they often remain untreated, with valuable tissues
allocated to patients with better chances of success.6
Artificial corneas or keratoprostheses (KPros) were developed
to treat high-risk patients, but most have failed due to adverse
biomaterial-induced host reactions. The most successful design
currently in clinical application, the Boston KPro, has a poly
(methyl methacrylate)(PMMA) optic cylinder that allows light
transmission into the eye for vision. However, human corneal
tissue is needed as a carrier for implantation. The graft-host tissue
interface has been implicated in the formation of retroprosthetic
membrane,7 corneal tissue melt (keratolysis) and tractional ret-
inal detachment. Further, the issues of PMMA-induced inflam-
mation remain8 and potentially contribute to periprosthetic
keratolysis and KPro extrusion.9 In a mouse model, it was shown
that inflammatory cytokines, TNF-α and IL-1, elicited by Boston
KPro implantation can result in optic nerve damage.10 Hence,
KPros are only used for end-stage eyes.
Diverse anti-inflammatory approaches have been developed to
improve biocompatibility and integration of biomaterial implants.
Many of these involve surface modification of the biomaterials.11
Introduction of topographical features on surfaces were reported
to reduce adherence of macrophages,12 and alter the profile of
cytokines produced in vivo in rats. Other strategies involve
converting hydrophobic surfaces that promote inflammatory
reactions (e.g., increased leukocyte adhesion, macrophage fusion,
and pro-inflammatory cytokine release13,14) to more tolerogenic
hydrophilic ones by modifying surface chemistries.11,13 Hydro-
philic terminal groups (NH2, OH, COOH) were shown to temper
macrophage conversion into foreign body giant cells that char-
acterize adverse reactions, and decrease expression of pro-
inflammatory cytokines.11 Inflammation-decreasing surface
coatings include anti-fouling molecules such as polyethylene
glycol (PEG) that prevent non-specific cell adhesion, and anti-
inflammatory molecules like glycosaminoglycans, steroids (e.g.,
dexamethasone), α-melanocyte-stimulating hormone, and
interleukin-1 receptor antagonists.11
Corneal transplantation, particularly in high-risk cases, can
trigger allogenic sensitization against foreign cells, releasing
inflammatory chemokines/cytokines that mediate the recruitment
and activation of immune cells including antigen-presenting
dendritic cells to the graft.15,16 Host dendritic cells are exposed to
shed donor antigen as they migrate into the graft. As the dendritic
cells process the alloantigens, they drain via the lymphatic system
to local lymph nodes where they activate naive T-cells that are
involved in rejection.15 The inflammatory cycle triggered by
dendritic cell activation also results in lymphangiogenesis and
angiogenesis, which in turn enhances the sensitization to
alloantigens.17 Implants that do not activate dendritic cells at the
outset would therefore be optimal.
To address corneal donor shortage and circumvent immune
problems, Fagerholm et al. developed corneal implants made
from carbodiimide-crosslinked recombinant human collagen type
III (RHCIII) and grafted 500 µm thick implants into 10
patients.18,19 Being cell-free, the implants were immune compa-
tible, did not activate dendritic cells, and supported the stable
regeneration of corneal epithelium, stroma, and nerves.19,20
Polymeric 2-methacryloyloxyethyl phosphorylcholine (MPC) was
incorporated into implants to modulate the inflammation in
corneas of patients at high-risk of graft rejection and therefore
not prioritized for donor corneal transplantation.21 Partial-
thickness RHCIII-MPC grafted into high-risk corneas after
removing active ulcers or scars promoted stable corneal epithe-
lium and stromal regeneration over the averaged 24-month
observational period.21 It was subsequently shown that MPC-
containing RHCIII hydrogels do not activate dendritic cells, but
instead induce dendritic cell apoptosis.20
While RHCIII-based implants performed well in clinical trials,
RHCIII is a large macromolecule with manufacturing challenges.
Replicating full-length native collagen, RHCIII contains numer-
ous 4-hydroxyproline amino acids for stable triple helix forma-
tion. Therefore, to produce RHCIII, it is not only necessary to
produce the collagen but also prolyl 4-hydroxylase, the enzyme
that catalyzes 4-hydroxyproline formation from proline.22 In
addition, recombinant pepsin is needed to cleave the telopeptides
from the full-length protein prior to use.23 This means the
expression of three different complex proteins is required to
produce RHCIII. Short, self-assembling collagen-like peptides
(CLPs) have been developed by several groups as alternatives to
native collagen.24 As short peptides, they can be produced syn-
thetically, are easy to purify and also easy to manipulate and
customize for different applications.24,25 A 36 amino-acid CLP
was developed by the Hartgerink group as a collagen analog,26
and performed well as a hemostat.27 When conjugated to a multi-
arm polyethylene glycol (PEG) through a short peptide and thiol-
maleimide, the resulting CLP-PEG hydrogel could be fabricated
into corneal implants that promoted regeneration in the corneas
of mini-pigs.28,29 However, the N-(3- dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC) used for stabilizing the
hydrogels was possibly pro-inflammatory.20,30
As mentioned above there are currently no or limited treat-
ment options for patients awaiting corneal transplantation that
are at high-risk of graft rejection. Our goal was thus to bioengi-
neer fully synthetic, robust and easy to manufacture corneal
implants, as alternatives to human donor corneas or prostheses.
In addition to a simple manufacturing process, the implants must
promote tolerogenic properties or limit inflammation while sti-
mulating stable regeneration of corneal tissues and nerves, to be
amenable for use in high-risk patients. Hence, we improved on
CLP-PEG implants by stabilizing with 4-(4,6-Dimethoxy-1,3,5-
triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) a
triazine-based crosslinker, as opposed to using the pro-
inflammatory EDC stabilizer. Indeed, DMTMM has a much
lower toxicity compared to EDC and its commonly used co-
reactant, N-hydroxy-succinimide (NHS).31 We further modified
the CLP-PEG implants by including inflammation-suppressing
MPC. The CLP-PEG-MPC implants were characterized and
compared to those without MPC in vitro and after grafting into
the corneas of mini-pigs. Inflammation and severe pathological
conditions were simulated by a standard alkali burn
cornea model.
Results
Hydrogel manufacture and characterization. Infrared spectro-
scopy (Fig. 1a) and 31P NMR spectroscopy (Fig. 1b) confirmed
the incorporation of MPC into DMTMM-crosslinked CLP-PEG
hydrogels that were fabricated into cornea-shaped implants,
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10 mm in diameter and 500 µm thick. In particular, the CLP-
PEG-MPC hydrogels showed a peak at approximately 0 ppm on
31P NMR, which was indicative of the ring opening generated by
the addition of trimethylamine to the 2‐hydroxyethyl methacry-
late (HEMA) and ethylene chlorophosphate intermediary during
MPC synthesis (Fig. 1b).32 Both hydrogels were highly trans-
parent in visible light (%T400 nm–700 nm > 80%) (Fig. 1c).
However, CLP-PEG-MPC (Fig. 1c), but not CLP-PEG, hydrogels
blocked up to 60% transmission of UV-A (300–400 nm
wavelength).
Table 1 summarizes the implant properties and how they
compare with RHCIII implants that were tested clinically, and to
human corneas. Neither hydrogels nor the RHCIII comparator
were as tough as the human cornea, although they were optically
slightly superior. As the hydrogels contained over 90% water,
































































































































Fig. 1 Chemical and optical analyses of CLP-PEG-MPC and CLP-PEG hydrogels. a Fourier transformed infrared spectroscopy shows the incorporation of
the CLP-PEG monomer (lavender line) into the CLP-PEG hydrogel (black line) the CLP-PEG monomer and MPC monomer (purple line) into the CLP-PEG-
MPC hydrogel (pink line). b 31P NMR spectroscopy with peaks that show the incorporation of phosphorylcholine (purple line) into CLP-PEG-MPC
hydrogels (pink line) (n=1, per group). c Both CLP-PEG (black line) and CLP-PEG-MPC (pink line) hydrogels transmit the full spectrum of visible light, but
CLP-PEG-MPC blocks short UV wavelengths (n=1, per group). d, e Apparent and cumulative permeability of 700 Da Alexa Fluor® 568 hydrazide sodium
salt through CLP-PEG-MPC hydrogels (pink squares, n=4 technical replicates (TR)) in comparison to 12 and 8% CLP-PEG (black circles, n=4; light blue
triangles, n=3 TR, respectively) hydrogels and hAM (gray inverted triangles, n=3 TR). f Both CLP-PEG-MPC (pink squares) and CLP-PEG hydrogels (black
circles) remained stable and minimally degraded when exposed to collagenase enzyme (n=3 TR per group).
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PEG hydrogels were stiffer (Young’s modulus of 0.150 ± 0.015
MPa) and less elastic (elongation at break 49.96 ± 8.10 %) than
those incorporating MPC. CLP-PEG-MPC implants displayed a
lower Young’s modulus (0.044 ± 0.010MPa) and higher
elongation at break (59.50 ± 7.70 %). Furthermore, rheology
showed that the CLP-PEG hydrogels had a higher storage
modulus (G′) (22.36 ± 1.489 kPa) than the CLP-PEG-MPC
(15.15 ± 1.086 kPa) indicating an increased amount of structure
present in the CLP-PEG only implants. However, considering the
loss modulus of both gels was lower than the storage modulus,
both hydrogels were considered ductile. Apparent and cumulative
permeability measurements of the implants (Fig. 1d, e) showed
no significant difference in the apparent or cumulative perme-
ability amongst CLP-PEG-MPC, CLP-PEG, or the human
amniotic membrane (hAM) control, which is the current gold
standard for ocular surface reconstruction. Both CLP-PEG-MPC
and CLP-PEG implants were highly resistant to bacterial
collagenase degradation in vitro (Fig. 1f).
In vitro biocompatibility and immune compatibility. Initial
growth (1–6 days) of immortalized human corneal epithelial cells
(HCECs) expressing green fluorescent protein (GFP) on CLP-
PEG-MPC was slower than on CLP-PEG and tissue culture
plastic controls (Fig. 2a–c), but at 7 days in culture, cells on both
hydrogels were confluent (Fig. 2d, e). Live-dead staining showed
very few dead cells, confirming that the hydrogels were non-
cytotoxic (Fig. 2g, h). These observations were confirmed by an
Alamar Blue proliferation study carried out with non-GFP-tagged
HCECs (Fig. 2j; Supplementary Table 1). Bone-marrow-derived
dendritic cell (BMDC) activation assays were conducted for the
individual hydrogel components (Fig. 2k) and the completed
hydrogels (Fig. 2l). The crosslinker EDC-NHS was compared to
equimolar concentrations of DMTMM. However, EDC-NHS was
cytotoxic and resulted in such low absolute cell counts of CD11c+
cells, that it was excluded from subsequent analysis. Of the
structural hydrogel components, only conjugated CLP-PEG
activated CD40 (Fig. 2k). Both hydrogels upregulated CD40 to
levels above that of the untreated controls, but significantly lower
than the lipopolysaccharide positive control level (F= 40.03,
p<0.0001) (Fig. 2l).
In vivo clinical evaluation of implants. In compliance with the
Swedish Animal Welfare Ordinance and the Animal Welfare Act,
the mini-pig study was approved by the animal ethics committee
in Stockholm (N209/15). One cornea each of eight Göttingen
mini-pigs was subjected to an alkali burn, while the contralateral
untreated corneas served as controls. Alkali burns caused swelling
of the ocular surface and lids, tearing for 2 weeks, squinting for up
to 1 month, and corneal opacity (Figs. 3a, b, 4a). At 15 weeks
post-burn, inflammation had resolved but the corneal haze
remained (Figs. 3c, d, 4a, Supplementary Table 2). There were no
changes to the pigs’ body weights and overall health status due to
the burns or implantation of CLP-PEG-MPC and CLP-PEG
hydrogels.
All cell-free implants epithelialized by the 7-week post-operative
examination when the sutures used to stabilize the implants were
removed. Between 7 weeks and 3 months post-operation, corneal
haze increased (Fig. 3e–h, Fig. 4a, Supplementary Table 2) as
stromal cells began migrating into the implants as visualized by
in vivo confocal microscopy (IVCM). The Cochet–Bonnet
aesthesiometer measures the pressure needed to produce a blink
response by progressive shortening of a retractable nylon
monofilament. Aesthesiometry showed decreased touch sensitivity
that was most prominent at the 7-week and 3-month follow-ups,
correlating to the corneal nerves being damaged during the
surgery (Fig. 4b, Supplementary Table 3).
From 3 to 6 months post-operation, corneal haze decreased
(Figs. 3g–j, 4a, Supplementary Table 2) while touch sensitivity
increased as the newly remodeled areas became re-innervated
(Fig. 4b, Supplementary Table 3). At 9 and 12 months post-
operation, corneal haze was reduced to a light haze with a clinical
score of 1 (Figs. 3k, l, 4a, Supplementary Table 2) while
aesthesiometry showed touch sensitivity equivalent to that in
unoperated corneas (Fig. 4b, Supplementary Table 3). IVCM
confirmed the presence of a fully regenerated corneal epithelium
(Fig. 3m, n), and regenerating sub-basal nerve plexus (Fig. 3p, q)
and stroma (Fig. 3s, t) comparable to the controls (Fig. 3o, r, u).
The endothelium, which was untouched during the surgery,
remained intact (Fig. 3v, w) like the control (Fig. 3x).
The CLP-PEG-MPC implanted corneas maintained a thickness
of 745 ± 83 µm (mean ± SEM) at 3 months post-op to 773 ±
60 µm at 12 months post-operation, comparable to that of
unoperated contralateral corneas which were 789 ± 18 at
3 months and 801 ± 16 at 12 months (Fig. 4c, Supplementary
Table 4). CLP-PEG only implanted corneas, however, showed a
significant thickness increase of approximately 200 µm that was
most pronounced at 3 months post-operation, persisting and
remaining significant compared to the unoperated control (p =
0.0365) at 12 months post-operation.
Schirmer’s tear test showed that the alkali burn decreased
tear production (Fig. 4d, Supplementary Table 5). However,
tear production recovered and remained within normal values
thereafter. Intraocular pressure was unaffected by the burn or
hydrogel implantation, remaining within normal ranges of
Table 1 Characterization of CLP-PEG-MPC hydrogels compared to CLP-PEG only hydrogels, biosynthetic implants currently in




Tensile strength (MPa) 0.022 ± 0.004 0.56 ± 0.21 0.286 ± 0.0619 3.81 ± 0.4048
Elongation (%) 59.50 ± 7.70 49.96 ± 8.10 20.149 ± 7.61419 N/A
Young’s modulus (MPa) 0.044 ± 0.010 0.150 ± 0.015 1.749 ± 0.78219 3-1349, 50
Storage modulus (G′) (kPa) 15.15 ± 1.086 22.36 ± 1.489 – –
Loss modulus (G″) (kPa) 0.1522 ± 0.0569 0.0433 ± 0.006 – –
Transmission (%) 29-80(UV) 80-97(Vis) 32-92(UV) 92-99(Vis) 95.1 ± 0.0519 87.1 ± 2.0 (at 500 nm)51
Refractive index 1.340 ± 0.005 1.338 ± 0.004 1.3507 ± 0.001152 1.423–1.43653
Water content (%) 90.94 ± 0.78 92.67 ± 0.85 91.5 ± 0.919 7854
Residual mass (%) from collagenase
Degradation at 48 h
100.17 ± 3.54 96.19 ± 1.89 <10%52 –
aRHCIII implants that have been stably grafted into 10 patients and showed regeneration at 4 years post-operation as reported in Fagerholm et al.19 The n=3 technical replicates per group for CLP-PEG-
MPC, CLP-PEG and biosynthetic implants. Human cornea n-value varies by study.
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8–20 mmHg over the entire study (Fig. 4e, Supplementary
Table 6).
Implants were also grafted into the corneal stroma of a cat after
ethical permission from the Maisonneuve-Rosemont Hospital
Committee for Animal Protection and in accordance with the
Association for Research in Vision and Ophthalmology Statement
for the Use of Animals in Ophthalmic and Vision Research
(Supplementary Note 1). The implants were grafted using limbal
incisions at a depth of 350 µm (center of the stroma). Unlike the
mini-pigs, the cat cornea was healthy and the implants served as
inlays of 4 mm in diameter and 200 µm thickness. In the absence
of alkali burns, both CLP-PEG-MPC and CLP-PEG implants
remained optically transparent over the 14-month follow-up
period (Supplementary Fig. 1, 2). Optical coherence tomography
(OCT) showed the presence of clear implants at 14 months post-
operation (Supplementary Fig. 3). The edges of the implants
showed haziness on both OCT and slit-lamp imaging, which
could be edge artefacts or cells that have migrated to the implants.
Histopathology of implanted mini-pig corneas. Histopathology
on the mini-pig eyes was performed by a certified, 3rd party
veterinary pathologist (vivo Science GmbH, Gronau, Germany).
The alkali burned corneal samples excised during implantation
showed morphologically detectable corneal tissue damage char-
acterized by focal epithelial erosion, multi-focal epithelial hyper-
plasia, and stromal hypercellularity together with dissociation and
irregularity of the collagen fibers. The pathology observed was in
accordance with established descriptions of post-burn healing.33
At 12 months post-grafting, both regenerated CLP-PEG and
CLP-PEG-MPC implanted corneas resembled healthy unoperated
corneas (Fig. 5a–c, Fig. 6a). Although hyperplasia was more
Fig. 2 In vitro analyses of CLP-PEG-MPC and CLP-PEG hydrogels. a–f GFP-tagged human corneal epithelial cells proliferated on both CLP-PEG-MPC and
CLP-PEG hydrogels over 7 days (n=4 per group). White scale bars, 1 mm. g–i Live/dead pictures of human corneal epithelial cells proliferated on both CLP-
PEG-MPC and CLP-PEG hydrogels over 6 days (green represents live cells and magenta represents dead cells) (n=5 per group). Red scale bars, 200 µm.
j Alamar Blue proliferation study of human corneal epithelial cells proliferated on CLP-PEG-MPC hydrogels (pink squares), CLP-PEG hydrogels (black
circles) and tissue culture plate controls (aqua triangles) at different time points (n=5 TR per group). Analysis by one-way ANOVA with Tukey’s multiple
comparisons test within each time point. k Culture of BMDCs on monomeric hydrogel components and crosslinkers showed no activation as determined by
the significantly lower expression of co-stimulatory receptors CD40-APC (blue squares), CD80-PE (orange triangles) and CD86-FITC (yellow inverted
triangles) compared to lipopolysaccharide (LPS) stimulation, a positive control for dendritic cell activation. Analysis by one-way ANOVA with Dunnett’s
multiple comparisons test (n=6 biological replicates (BR) per group). *LPS vs component, p<0.0001, †CLP-PEG vs component, p<0.05. l CLP-PEG-MPC
and CLP-PEG hydrogels do not upregulate CD40-APC (blue squares), CD80-PE (orange triangles) or CD86-FITC (yellow inverted triangles). One-way
ANOVA with Tukey’s multiple comparisons test. *LPS vs hydrogel, p<0.0001.
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noticeable in CLP-PEG regenerated corneas than CLP-PEG-
MPC, there were no significant difference (p=0.981, Supplemen-
tary Table 7). There was no difference in neovascularization
either (p=1.000). Descemet’s membrane, which delineates the
stroma from the underlying endothelium was intact, showing that
neither the burns nor implants extended through to the
endothelial compartment.
Immunohistochemistry on regenerated mini-pig neo-corneas.
Immunohistochemistry showed the regeneration of a tear film
(Fig. 5d–f), terminally differentiated corneal epithelium
(Fig. 5g–i), and cornea-specific collagen V in the stroma
(Fig. 5j–l). Immunohistochemical staining for α-smooth muscle
actin and CD31 as markers of blood vessels, lymphatic vessel
endothelial hyaluronan receptor 1 (LYVE1) as markers of lym-
phatic vessels and CD172a as a marker of myeloid cells showed a
trend towards higher expression in CLP-PEG implanted corneas
(Fig. 6b, Supplementary Fig. 4, Supplementary Table 8).
Expression of cathelicidin peptide LL37, a host-defence peptide,
showed no marked differences (Supplementary Fig. 5).
Biochemical analyses on regenerated mini-pig neo-corneas.
Proteins extracted from regenerated neo-corneas contained sig-
nificant levels of type I and type V collagens, the main corneal
collagens (Fig. 6c). These results suggest that host cells had syn-
thesized a collagenous matrix enriched in the same collagen types
as are found in the normal cornea. Overall, there were differences
in the amounts of individual α chains, β-dimers and γ trimers of
collagen between CLP-PEG-MPC and CLP-PEG only implants.
CLP-PEG-MPC has equivalent amounts of covalently crosslinked
high molecular weight collagen to unoperated corneas, but
showed decreased amounts of individual α chains, β-dimers and γ
trimers compared to the CLP-PEG and unoperated groups. CLP-
PEG implants had significantly less cornea-specific type V (α1
(V)) collagen than CLP-PEG-MPC or untreated corneas (Fig. 6c,
Supplementary Table 9).
Fig. 3 CLP-PEG-MPC implants in alkali burned mini-pig corneas compared to CLP-PEG only implants. a–l Surgical progression of CLP-PEG-MPC
hydrogels compared to CLP-PEG hydrogels implanted in mini-pig corneas following alkali burns. Corneal haze was seen immediately after the alkali burn to
the central cornea (a, b) and is still present just before surgery (c, d). After surgery, haze is present up to 6 months (e–j) and is decreased by 12 months
post-operation (k–l). m–u In vivo confocal microscopy of the regenerated CLP-PEG-MPC and CLP-PEG neo-corneas at 12 months post-operation in
comparison to unoperated corneas, showing regeneration of corneal epithelium, subepithelial nerves (arrowheads) and stroma. The unoperated
endothelium (v–x) remains intact. White scale bars, 100 µm.
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Electron microscopy on regenerated mini-pig neo-corneas.
Serial block face scanning electron microscopy (SBF-SEM)
(Fig. 7a–f) and transmission electron microscopy (Fig. 7g–i)
showed that both neo-corneas resembled naïve corneas, except
that the basal aspect of their basal epithelial cells showed
numerous invaginations. SBF-SEM also revealed a more regular
lamellar keratocyte arrangement in CLP-PEG-MPC neo-corneas
(Fig. 7a, d) resembling that of the healthy, unoperated controls
(Fig. 7c, f). However, the CLP-PEG neo-corneas had more
unevenly spaced stromal keratocytes with fewer cell layers
(Fig. 7b, e), suggesting a still-evolving morphology.
Extracellular vesicles and exosomes. Intense staining for Tsg101-
positive extracellular vesicles (EVs) was seen in CLP-PEG neo-
corneas (Fig. 8b) compared to unoperated controls (Fig. 8c).
Colocalization of Tsg101 and the exosomal surface marker CD9,
showed that many of the EVs were exosomes (Fig. 8e). The CLP-






















































































































































































































COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02108-y ARTICLE
COMMUNICATIONS BIOLOGY |           (2021) 4:608 | https://doi.org/10.1038/s42003-021-02108-y | www.nature.com/commsbio 7
Fig. 4 Clinical follow-up of regenerating neo-corneas after CLP-PEG and CLP-PEG-MPC implantation into post-alkali burned mini-pig corneas. a
Corneal haze increased in response to alkali burn and surgery in CLP-PEG (black circles) and CLP-PEG-MPC (pink squares) but diminished over the 12-
month follow-up period. b Corneal blink response measured by Cochet-Bonnet aesthesiometry showing immediate decrease post-surgery in CLP-PEG-
MPC (pink squares) and CLP-PEG (black circles) with recovery to pre-operative levels by 12 months. Unoperated eyes (aqua triangles) do not show
changes in the blink response. c CLP-PEG-MPC (pink squares) grafts resulted in a corneal thickness comparable to the unoperated eye (aqua triangles), but
CLP-PEG (black circles) resulted in significant increases in corneal thickness. d Schirmer’s tear tests showing a decrease in tear production immediately
post-burn due to trauma, followed by a normal tear production in CLP-PEG-MPC (pink squares) and CLP-PEG (black circles) compared to unoperated
controls (aqua triangles). e Intraocular pressure was maintained within normal parameters CLP-PEG-MPC (pink squares), CLP-PEG (black circles) and
unoperated (aqua triangles) corneas throughout all stages of follow-up. Data displayed as mean ± SEM. Statistical analyses by two-way repeat measures
ANOVA with Geisser’s Greenhouse correction and a Tukey’s or Sidak multiple comparison test. *Unoperated vs CLP-PEG, p<0.05. †Unoperated vs. CLP-
PEG-MPC, p<0.05. ‡ CLP-PEG vs. CLP-PEG-MPC, p<0.05. For all charts the unit of analysis is the eye: CLP-PEG n=4, CLP-PEG-MPC n=4, unoperated
n=8.
Fig. 5 Regenerated mini-pig neo-corneas at 12 months after post-CLP-PEG-MPC implantation compared to CLP-PEG and controls. a–c Hematoxylin and
eosin staining of the implanted corneas shows morphological similarity of the regenerated epithelium (rE) and stroma (rS) to the epithelium (E) and stroma
(S) of an unoperated, healthy control cornea. The unoperated endothelium (arrowheads) remained intact in all samples. d–f Positive Ulex Europaeus
Agglutinin lectin staining shows the presence of a tear film in both regenerated corneas and the control. g–i Terminally differentiated corneal cells were
cytokeratin 3/76-positive in both regenerated neo-corneas. j–l Collagen V staining of the neo-cornea stromas shows the regeneration of corneal specific
ECM components. Black scale bars, 500 µm; white scale bars, 200 µm.
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(Fig. 8a) and exosomes (Fig. 8d) compared to the unoperated
control corneas (Fig. 8c, f). TEM of the corneal basement
membrane showed the presence of exosomes in both grafted
materials (Fig. 8g, h, j, k) but observably more copious amounts
in the CLP-PEG neo-corneas.
Discussion
Our aim was to develop a fully synthetic peptide-based corneal
implant with inflammation-suppressing properties. We showed
that CLP-PEG-MPC implants, like previously described CLP-
PEG ones, were readily and reliably mouldable.29 Both implants
had refractive indices of 1.34, in keeping with their high water
content. However, while both implants were highly transparent in
visible light, CLP-PEG-MPC but not CLP-PEG implants filtered
up to 60% of potentially damaging UV-A, which is essential for
lens and retina protection (from cataract and macular degen-
eration). CLP-PEG hydrogels were stiffer and less elastic than
those containing MPC. Interestingly, a similar trend was pre-
viously observed upon incorporation of MPC within RHCIII
implants.39 Although the CLP-PEG-MPC implants had lower
overall tensile strength, their elasticity made them sufficiently
robust for surgical handling and implantation with overlying
sutures. Neither hydrogel was as tough as the human cornea, but
they had properties close to those of RHCIII corneal implants
successfully tested in a clinical trial for over four years.18,19 Here,
as in Fagerholm et al.,19 the original implant was remodeled
during corneal regeneration. Furthermore, Jangamreddy et al.29
showed that the weaker, cell-free CLP-PEG hydrogels implanted
into rabbit corneas transformed into regenerated neo-corneas
with mechanical properties approximating those of healthy,
unoperated corneas, the desired end-points. Here, the objective
was to synthesize a decreased-cost, peptide-based implant with
the immunosuppressive qualities of MPC.
Both hydrogels supported HCEC proliferation in vitro, with
the slower initial growth on the MPC-containing gels attributed
to the non-adherent “slippery” nature of phosphorylcholine-
derived hydrogel surfaces.34,35 When evaluating the effect of
crosslinking agents on the activation of dendritic cells, EDC-NHS
was cytotoxic and killed the cells at levels where DMTMM yielded
live cells with minimal activation compared to positive LPS
controls. These observations correlate with Samarawickrama
et al.31, who showed that 0.5% (w/v) EDC-NHS was more toxic
than 1% (w/v) DMTMM. The components and prepared CLP-
PEG and CLP-PEG-MPC hydrogels had significantly lower
capacity to activate dendritic cells compared to LPS. Hence, the
hydrogels would be well-tolerated as implants.
The alkali burn cornea model is a well-established ophthal-
mology model of severe pathology in rodents and rabbits,
resulting in marked inflammation and often neovascularization.
In a study by Rehany and Waissman, 20 rabbits with alkali burns
required intramuscular injections of 25 mg/kg cyclosporin A daily
for 30 days post-operation to allow allograft tolerance.36 Rabbits
that did not receive an intensive steroid regimen uniformly
rejected the allografts following severe vascularization. Here, we
adapted the alkali burn model to Gottingen mini-pig corneas. A
certified veterinary pathologist confirmed the resulting burn
pathology of stromal disruption and hypercellularity in the





































































Fig. 6 Histopathological, immunohistochemical and biochemical
characteristics of regenerated neo-corneas at 12 months post-
implantation with CLP-PEG-MPC implants compared to CLP-PEG
implants. a Corneal epithelial hyperplasia was noticeably higher in the CLP-
PEG only implants (black circles) compared to CLP-PEG-MPC implants
(pink squares), while neovascularization was not markedly different.
However, neither was statistically significant by the Mann–Whitney U test.
b Mean cell counts normalized to the contralateral control eye for
myofibroblast α-smooth muscle actin, blood vessel marker CD31, lymphatic
vessel marker LYVE1, and the myeloid cell marker CD172a show no
significant differences between CLP-PEG-MPC (pink squares) and CLP-PEG
(black circles). Statistical analysis by unpaired, two-way t-test were
performed with statistical significance set at p≤0.05. c Collagen content
analysis of the central cornea in CLP-PEG-MPC (pink squares), CLP-PEG
(black circles) and unoperated (aqua triangles) corneas. Statistical analysis
of collagen by two-way ANOVA with Tukey’s multiple comparisons test.
Data are displayed using the mean. *Unoperated vs CLP-PEG, p<0.05.
†Unoperated vs. CLP-PEG-MPC, p≤0.05. ‡ CLP-PEG vs. CLP-PEG-MPC,
p≤0.05. For all charts the unit of analysis is the eye: CLP-PEG n=4, CLP-
PEG-MPC n=4, unoperated n=8.
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Both CLP-PEG-MPC and CLP-PEG implants showed healing
and regeneration over the 12-month post-operation period, in the
absence of steroids or immunosuppressive drugs. The presence of
terminally differentiated epithelial cells, regenerated tear film and
host-defence peptide, LL37, showed that both hydrogels pro-
moted functional epithelial regeneration. However, CLP-PEG-
MPC implants had significantly reduced corneal epithelial
hyperplasia and stromal thickening, supporting the contention
that MPC suppresses corneal inflammation. While not apparent
in H&E histopathology sections, immunohistochemistry revealed
that CLP-PEG-MPC implanted corneas also showed a trend
towards reduced blood and lymphatic vessels and fewer myeloid
cells in the graft site. The phosphorylcholine network appeared to
decrease corneal haze and improve the rate of nerve regeneration
to restore the corneal blink response. Unfortunately, although
CLP-PEG-MPC showed a trend towards improved performance,
the small number of pigs in each experimental group used due to
cost constraints of performing a certified GLP study in a large
animal model, did not allow sufficient power to discriminate and
show statistical significance.
CLP-PEG-MPC corneas expressed lower amounts of mono-
meric (α), dimeric (β), and trimeric (γ) collagen than CLP-PEG
implanted ones, although they expressed similar amounts of
crosslinked collagen fibrils (HMW) to unoperated controls. More
interestingly, the CLP-PEG-MPC implanted corneas had higher
amounts of type V collagen, which is a collagen that is present in
the corneas in enhanced amounts and shown to be involved in
the maintenance of corneal transparency.37 CLP-PEG-MPC
implants also had a lower amount of EVs and exosomes than
CLP-PEG implanted corneas. CLP-PEG has previously been
shown to stimulate regenerating corneal cells to produce large
amounts of cornea-specific type V collagen associated
exosomes.29 Taken together, these results strongly suggest that
regenerated CLP-PEG-MPC neo-corneas were at a more
advanced stage of corneal regeneration than the CLP-PEG ones,
with more type V collagen in its extracellular matrix, possibly due
to the modulation of inflammation in the former.
The CLP-PEG biomaterial in the alkali burned corneas resulted
in low-grade haze throughout the 12-month follow-up period
with blood vessels in three of four pigs. Incorporation of MPC
decreased the haze in the regenerated neo-tissues but they did not
reach full optical clarity. There were also residual traces of neo-
vascularisation. However, when CLP-PEG-MPC and CLP-PEG
hydrogels were implanted within the stroma of a healthy, non-
burned cat cornea, both implants remained optically transparent
over 14 months. Both hydrogels performed equivalently as low-
risk implants, with the presence of MPC only noticeable under
high-risk grafting conditions.
The CLP-PEG-MPC implants were therefore able to restore the
alkali burned corneal environment to one that resembled an
Fig. 7 Electron micrographs of regenerated neo-corneas after CLP-PEG and CLP-PEG-MPC implantation. Serial block face scanning electron microscope
overview scans show comparable epithelial and stromal compartments (a–c). 3D reconstructions (d–f) of the neo-corneas after digital removal of the
extracellular matrix show that keratocytes within the stroma are arranged in interconnected lamellae. The lamellae in the CLP-PEG only implanted corneas
are less organized than in the other two groups. g–i Transmission electron microscopy of the corneas indicates that both operated groups (g, h) have
invaginated basal epithelia. E, epithelium; S, stroma; r, regenerated.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02108-y
10 COMMUNICATIONS BIOLOGY |           (2021) 4:608 | https://doi.org/10.1038/s42003-021-02108-y | www.nature.com/commsbio
uninflamed state, allowing regeneration of corneal epithelium,
stroma and nerves. The presence of MPC circumvented the
increased thickness seen in the non-MPC-containing implants.
These results confirm the decreased neovascularization observed
in rabbits38 and the stable regeneration of six high-risk patients
with active ulcers and scarring in a clinical trial using full-length
RHCIII-MPC implants.21 Combined, these studies show that
MPC is an effective inflammation-suppressing polymer that also
imparts elasticity to the overall hydrogel. The novelty of the
present study is that CLP-PEG-MPC implants combine inflam-
mation suppression with a fully synthetic collagen analog com-
prising CLP and PEG. The short, synthetically produced CLPs are
readily manufactured without the need for co-expression of
several full-length proteins needed to produce recombinant
human collagen and avoids possible xenogeneic-origin allergy39
or zoonotic transmission of pathogens such as viruses that
may result from animal-derived materials.40 Furthermore, the
use of synthetic analogs allows for future modification and
customization of implants for personalized medicine, which is
difficult with more chemically inert full-length collagens. The
results indicate that evaluation of CLP-PEG-MPC implants in a
clinical trial is merited.
With a formidable 12.7 million patients on waiting lists
worldwide for corneal transplantation and a severe shortage of
human donor corneas, CLP-PEG-MPC implants may in the near
future be an alternative treatment, and further address the unmet
need of patients with inflammation and severe conditions who are
not amenable to standard donor corneal tissue transplantation.
Methods
Fabrication. CLP (CG(PKG)4(POG)4(DOG)4) (AmbioPharm, SC, USA) was
conjugated to an 8-arm poly(ethylene glycol) with a hexaglycerol core (Sinopeg
Biotech Co. Ltd., Beijing, China).28 In brief, CLP was conjugated to PEG at pH 4.5,
sterile filtered and dialyzed using a 12–14 kDa membrane to remove unreacted
CLP. The product was lyophilized and re-dissolved at 12% (w/w). CLP-PEG
hydrogels were produced using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-
morpholinium chloride (DMTMM) at molar ratio of 1:2 CLP-PEG:DMTMM.
Fig. 8 Extracellular vesicles and exosome secretion by regenerating CLP-PEG-MPC and CLP-PEG implanted corneas. a–c Greater amounts of Tsg101+
EVs (red staining) were present in the grafted regions, with the highest level of secretion in the CLP-PEG implants compared to CLP-PEG-MPC implants
and unoperated controls. DAPI (blue staining) was used to identify the cell nuclei. d–f CLP-PEG implants also had the highest amount of Tsg101+, CD9+
exosomes represented by yellow staining. White scale bars, 200 µm. g–i High resolution TEM of the basement membrane confirms the increased release
of exosomes from the epithelium into the stroma. Black scale bars, 2 µm. j–l High magnification of the inset yellow-boxed areas showing the presence of
exosomes (white arrowheads) in the stroma. Yellow scale bars, 500 nm.
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02108-y ARTICLE
COMMUNICATIONS BIOLOGY |           (2021) 4:608 | https://doi.org/10.1038/s42003-021-02108-y | www.nature.com/commsbio 11
CLP-PEG-PC implants were manufactured using an additional phosphorylcholine
network based on the interpenetrating network from our previous recombinant
human collagen type III-phosphorylcholine implants.21 The phosphorylcholine
network is composed of 2-methacryloyloxyethyl phosphorylcholine (MPC)
(Paramount Fine Chemicals, Beijing, China) and polyethylene glycol diacrylate
(PEGDA) (Sigma-Aldrich, St. Louis, MO) The ratio of CLP-PEG:MPC was 2:1
(w/w) and MPC:PEGDA was 3:1 (w/w). Ammonium persulfate and N,N,N′N’′-
tetramethylethylenediamine (Sigma-Aldrich, St. Louis, MO) were both used as
polymerization initiators at a ratio of MPC:APS of 1:0.03 and APS:TEMED of
1:0.77. Corneal implants were cast as 10 mm diameter, 500 µm thick curved
hydrogel molds (custom manufactured by Formteknik, Anderstorp, Sweden).
Dogbone-shaped hydrogels of the same thickness were used for physical,
mechanical and in vitro testing.
The CLP-PEG-MPC and CLP-PEG hydrogel implants used in the in vivo mini-
pig study and supplemental cat study were custom manufactured by UAB Ferentis
(Vilnius, Lithuania) and stored in PBS containing 1% chloroform.
NMR spectroscopy. Incorporation of MPC into the CLP-PEG-MPC hydrogels
was assessed with 13C and 31P Cross Polarization Magic-Angle Spinning (CPMAS)
nuclear magnetic resonance (NMR) spectroscopy on a Bruker AVANCE 400 MHz
spectrometer at room temperature. CLP-PEG only hydrogels served as negative
controls. 13C NMR produced convoluted spectra in the region between 55 and
70 ppm that made it difficult to interpret, but 31P NMR gave definitive peaks. Peak
analysis was performed using Mnova (Mestrelab Research, Santiago de Compos-
tela, Spain).
Young’s modulus and mechanical strength. Dogbone-shaped hydrogels (500 μm
thick) were evaluated using an Instron electromechanical universal tester (Model
3342, Instron, Norwood, MA) equipped with Series IX/S software. The hydrogels
were washed in 1X PBS for 1 h before testing and blotted to remove excess water.
The elongation tests were performed using a crosshead speed of 10 mm min‒1.
Rheology. Circular hydrogels, 8 mm in diameter and 500 µm thick, were tested
using a Discovery Hybrid-2 rheometer (TA Instruments, New Castle, DE, USA)
fitted with an 8 mm circular geometry. After blotting to remove excess water, the
hydrogels were compressed to an approximate pressure of 1 N of axial force. An
amplitude sweep was run from 0.1 to 500% using an angular frequency of 10 rad/s.
Analysis was conducted using Trios v5.1.1.46572 (TA Instruments, New Castle,
DE, USA).
Light transmission of hydrogels. Flat hydrogel sheets of 500 µm thickness and
5 mm × 10 mm dimensions were evaluated for light transmission between 250 nm
and 800 nm. Each hydrogel was placed on the inside wall of a quartz cuvette filled
with PBS. The absorption was read using a Spectramax M2e series plate/cuvette
spectrophotometer (Molecular Devices, San Jose, CA, USA). A cuvette filled with
PBS was used as the baseline reference. The percent transmission was calculated
from the measured absorbances.
Refractive index. The refractive index of the hydrogels was measured at RT on an
Abbemat 300 (Anton Parr) refractometer.
Water content of hydrogels. A baseline measurement of a blotted hydrogel was
obtained as the starting “wet weight” (W0) of the hydrogel. The hydrogels were
then dried until a stable “dry weight” (W) was obtained. The percent water
content of the hydrogels (Wt) was calculated according to the equation: Wt % =
(W−W0)/W %.
Collagenase degradation. Samples were equilibrated in Tris-HCl buffer (0.1 M,
pH 7.4) overnight. Hydrogels were then incubated in 5 mL 5 U/mL type I bacterial
collagenase dissolved in Tris-HCl at 37 °C. The undigested mass was weighed at
time 0 (W′0) and every 8 h (W′t) for 2 days (48 h). At every interval, surface water
was blotted away, and samples were weighed using an ultra-microbalance (SE2,
Sartorius, Göttingen, Germany). At every weighing occasion, the collagenase
solution was replaced with a fresh collagenase mixture. The percentage of mass
remaining after digestion was calculated according following equation: Residual
mass (%) = (W′t/W′0) × 100%.
Permeability. Permeability studies were conducted for two concentrations of CLP-
PEG hydrogels (12% and 8%) and one concentration of CLP-PEG-MPC hydrogel
(9%).41 Hydrogels or human amniotic membrane (hAM) were clamped in an
Ussing Chamber system (Physiologic instruments, San Diego, CA) with P2300
EasyMount Diffusion Chambers and P2307 sliders. A 700 Da Alexa Fluor® 568
hydrazide sodium salt (10 μM) was placed in aqueous solution in the donor
chamber and PBS was placed in the recipient chamber. Samples were drawn at
multiple time points and fluorescence was quantified using 590 nm excitation
wavelength and a 642 nm emission wavelength by a Wallac Viktor2 1420 Multi-
label counter (PerkinElmer, Waltham, MA, USA). The apparent permeability
coefficient (Papp, cm s−1) was calculated using the equation Papp = (dC/dt)/(60C0A)
[dC/dt is the slope, C0 the initial concentration of the donor chamber and A the
exposed surface area of the sample in the slider (0.031 cm2)]. Cumulative perme-
ability was calculated as the percentage of diffused fluorescent marker from the
donor chamber to the receiving chamber during the experiment.
Human corneal epithelial cell culture. A stable GFP-HCEC cell line was estab-
lished by the transfection of SV40 immortalized HCEC cells (Gift of H Handa,
Division of Ophthalmology, Kinki Central Hospital, Hyogo, Japan) with a vector
containing a puromycin-resistant gene together with GFP, using the Lipofectamine
2000 Transfection Reagent (Life Technologies, California, USA).42,43 Selection of
puromycin-resistant cells with 2 μg ml–1 of puromycin added to the medium was
performed to obtain stable GFP-expressing lines. The initial immortalized HCEC
line was characterized using the expression of keratin and large T antigen.42 GFP-
HCECs were subsequently characterized by morphology, and expression of
Integrin β1 and focal adhesion kinase cell proliferation rate.43 These cells were not
checked for mycoplasma contamination.
To conduct proliferation studies, CLP-PEG and CLP-PEG-MPC hydrogels were
punched using a 5 mm biopsy punch and placed in a 96 well plate. GFP-HCECs
were seeded into the control wells and onto the materials at a density of 5000 cells/
well. GFP-HCECs were supplemented with keratinocyte serum-free medium
(KSFM; Gibco, ThermoFisher, Waltham, MA, USA) containing 0.05 mg/mL
bovine pituitary extract, 5 ng/mL epidermal growth factor, and 1 mg/mL penicillin/
streptomycin and their growth monitored for 7 days in a humidified incubator at
37 °C and 5% CO2. Growth was assessed by photographing the cultured cells and
examining the % coverage of the culture dishes.
For the Alamar Blue and live dead studies, the hydrogels were cut into 6-mm-
diameter and overnight immersed in the cell culture media. 5,000 HCECs were
seeded on top of each hydrogel for culturing with keratinocyte serum-free medium
(KSFM) supplemented with 50 μg/ml bovine pituitary extract and 5 ng/ml
epidermal growth factor (EGF) (Gibco, California, USA) in a 37 °C and 5% CO2
incubator. Media was changed every alternative day. Cells seeded on tissue culture
plate (TCP) were used as control. The Alamar Blue study was performed at day 1,
day 4 and day 6 after cell seeding.44 At each time point, resazurin sodium salt was
added to the cell culture wells to obtain the final concentration of 0.004% (w/v) and
incubated for 3 h. Afterwards, the media was transfer to a new 96 well plate and
read on a BioTek plate reader (Synergy 2, BioTek Instruments; Winooski, VT) at
530/25 nm for excitation and 590/35 nm for emission. At day 6, live/dead staining
was performed with a staining kit (Life Technologies Corporation, Oregon, USA),
where cells were double-stained by calcein acetoxymethyl (Calcein AM) and
ethidium homodimer-1 (EthD-1). Images were taken by using a fluorescence
microscope (Zeiss Axio Observer Z1, Carl Zeiss Microimaging GmbH, Jena,
Germany).
Bone marrow-derived dendritic cell (BMDC) activation assay. Bone marrow
was isolated from the femur and tibia of 6- to 12-week-old male C57BL/6J mice
(Mus musculus). Cells (1×106/well) were seeded onto 6-well suspension culture
plates in RPMI 1640 containing 10% (v/v) fetal bovine serum (Wisent, Saint-Jean-
Baptiste, QC), 0.5 mg/mL penicillin-streptomycin-glutamine, 10 mM HEPES,
1 mM sodium pyruvate, 55 μm β-mercaptoethanol and 2.5 ng/mL granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Gibco, Waltham, MA). Com-
plete RPMI, containing 5.0 ng/mL GM-CSF, was exchanged for half of the media
on days 2 and 3 of culture. Cultures were maintained for 6 days, then collected and
subject to density gradient centrifugation using Histodenz™ (Sigma-Aldrich, St.
Louis, MO) to separate the enlarged BMDCs. The selected cells were seeded at a
density of 1x106 cells/well on a 24 well plate for materials testing.
Hydrogel components (EDC/NHS, DMTMM, CLP, CLP-PEG, and MPC) were
applied to the BMDCs at an equivalent total mass to a 10 mm, 500 μm thick
hydrogel disk, to simulate the total amount present in a complete corneal implant.
Hydrogels disks (6 mm diameter, 500 μm thick) were incubated with BMDCs for
24 h. Lipopolysaccharide (LPS) was used as a positive control. BMDCs were
collected and labeled with direct-conjugate antibodies for CD11c, CD40, CD80 and
CD86 (Supplementary Table 10) and Zombie Aqua™ Fixable Viability Kit
(BioLegend, San Diego, CA). Flow cytometry was performed using a BD LSR II
flow cytometer using FACSDiva as collection software and analyzed using FlowJo
software (Becton, Dickinson & Company). The cells were gated for size and
granularity using a FSC/SSC gate (Supplementary Fig. 6a), followed by a gate to
remove dead cells, based on low Zombie-Aqua (Supplementary Fig. 6b). The live
cells were gated for CD11c high, autofluorescence low (Supplementary Fig. 6c) and
this is the gate that was subject to subsequent analysis. Mature dendritic cells
composed 50–99% of the live gate, as there was significant cell death in BMDCs
exposed to the toxic crosslinker EDC-NHS.
In vivo study in Göttingen mini-pigs. A study to evaluate the safety and bio-
compatibility of CLP-PEG-MPC and CLP-PEG implants in mini-pigs was per-
formed in compliance with the Swedish Animal Welfare Ordinance and the
Animal Welfare Act, with ethical permission from the local ethical committee in
Stockholm (N209/15), and in accordance with OECD Principles of Good
Laboratory Practices (GLP), ENV/MC/CHEM (98) 17, 1997, by Adlego Biomedical
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AB (Stockholm, Sweden). All animals were examined prior to alkali burn, and after
alkali burn prior to surgical implantation of CLP-PEG or CLP-PEG-MPC hydro-
gels. The pig samples size is based on the standard amount for safety and tox-
icology testing (n=4 per group). The pigs were randomly allocated to the two
biomaterials groups by the veterinary team at Adlego AB (Solna, Sweden). The
corneal surgeons were blinded as to which of the CLP-PEG or CLP-PEG-MPC
implants were implanted in each pig cornea. No data were excluded from this study
and this study has not been replicated. The full GLP study report by Adlego AB is
available on Dryad.45
Eight female Göttingen mini-pigs (Sus scrofa domesticus) were placed under
general anesthesia and pre-treated with tetracaine 1% eye drops (Chauvin
Pharmaceuticals Ltd, UK). Alkali burns were created in the right corneas of each
pig. A 5 mm, circular piece of filter paper soaked in 1M NaOH was placed on the
right cornea of each animal for 60 seconds, followed by a thorough rinse in 0.9%
saline, by flooding the treated cornea to remove excess NaOH. Buprenorphine
(0.05 mg/kg, Vetergesic, Orion Parma, Finland) was administered at the end of the
procedure and when signs of pain and discomfort were observed during recovery.
The injured eyes received chloramphenicol eye drops (5 mg/mL, Santen), twice
daily for 8 days post-procedure. The alkali burns were evaluated by slit lamp under
sedation, 6 weeks after the procedure. A full clinical exam was performed at
13 weeks, immediately prior to surgery.
Each alkali burned cornea underwent an anterior lamellar keratoplasty (ALK)
procedure to replace the anterior 2/3 s of each scarred cornea. Under general
anesthesia, each alkali burned cornea (average thickness 750 µm) was trephined to
a depth of 500 μm using a 6.5 mm diameter Barron Hessberg trephine. A corneal
diamond knife was used to complete the lamellar dissection. A 500 μm thick CLP-
PEG-MPC or CLP-PEG only implant, purchased from UAB Ferentis (Vilnius, LT)
was trephined to a diameter of 6.75 mm, placed in the wound bed and sutured in
place using 10-0 nylon (MANI Ophthalmic, Tochigi, Japan). Six interrupted
sutures were used to retain the implants where possible; otherwise overlying
mattress sutures were used. Each operated eye received a single dose of 3 mg/mL
dexamethasone and 1 mg/mL tobramycin eye drops (Tobrasone, Alcon, Sweden) at
the end of surgery.
After surgery, the animals were examined daily for 10 days and then weekly.
The operated eye received one drop of Tobrasone three times daily for 5 weeks.
Suture removal was performed under general anesthesia at post-operative 7 weeks.
Full eye examinations under general anesthesia were performed at 7 weeks as well
as 3, 6, 9, and 12 months post-operation. Restrained, fully conscious pigs were
assessed for central corneal touch sensitivity in using a Cochet-Bonnet
aesthesiometer (Handaya Co, Tokyo, Japan). After topical anesthesia and
confirmation of the extinction of the corneal blink response, the eyes were also
tested for tear production using Schirmer’s tear test (TearFlo, Hub Pharmaceuticals
USA), under sedation and prior to general anesthesia. For the remaining
examinations, animals were examined under general anesthesia. Examinations
include measurements of intraocular pressure (TonoVet Tonometer, Icare Finland
Oy, Finland), and pachymetry (Handy Pachymeter SP-100, Tomey, AZ, USA). A
full slit lamp evaluation (Kowa SL-15 Portable Slot Lamp, Kowa Company, Ltd.,
Aichi, Japan) was conducted in the presence of fluorescein eye drops (Lidocaine-
fluorescein 4% + 0.25%, Chauvin Pharmaceuticals Ltd.) using the McDonald-
Shadduck scoring system to quantify anterior segment findings. Each eye was
scored from 0 to +4 on conjunctiva congestion, swelling and discharge, aqueous
flare, iris involvement, and percent corneal haze. Full thickness IVCM was
performed at peripheral and central portions of the implant and similar positions
in the unoperated corneas (Heidelberg HRT3 with Rostock Cornea Module with
HEYEX software, Heidelberg, Germany).
The pigs were euthanized at 12 months post-operation with an overdose of
pentobarbitol (100 mg/mL, Allfatal Vet, Omnidea, Sweden) and corneas were
dissected out with a 2 mm rim of surrounding conjunctiva. The center 2 mm of
each cornea was excised with a biopsy punch and snap frozen in isopentane chilled
with dry ice for collagen content analysis. The remaining cornea was then
quartered for further processing.
Histopathology of mini-pig corneas. One quarter of the cornea was fixed in 4%
paraformaldehyde in phosphate buffer for Haematoxylin and Eosin (H&E) staining
and histopathological analysis under GLP by a certified veterinary pathologist at
in vivo Science GmbH (Gronau, Germany). Standard H&E stained research sec-
tions were imaged using a Zeiss AxioObserver Z1 inverted light microscope using
the tiling function in Zen Blue v2.3 at 20x magnification (Carl Zeiss Microscopy,
Göttingen, Germany).
Collagen analysis of mini-pig central cornea. Frozen biopsied corneal samples
from within the surgical areas of both implanted and control corneas were thawed
and re-suspended in 10 mM HCl at a wet weight to volume ratio of 1:35. Pepsin
(Roche, catalog# 200911, lot#93100120) was added to a final concentration of
1 mg/ml from a 10 mg/ml stock solution prepared just before use. The samples
were digested with pepsin at 2–8 °C for 96 h and the soluble fraction was recovered
by centrifugation in a microfuge at 16,000g for 30 min at 2–4 °C. An aliquot of the
pepsin soluble fraction was mixed with NuPAGE 4X LDS sample buffer (Life
Technologies) denatured at 75 °C for 8 min and analyzed on 3–8% Tris-acetate
gels under non-reducing conditions. Proteins were visualized by staining with
Gelcode Blue (Pierce). Prestained broad range marker (New England Biolabs,
catalog# P7712) and porcine skin type I collagen (Koken Co. Ltd., Japan) were used
as molecular weight standards. To quantitate the amounts of type I and type V
collagens in control and operated corneas, densitometric scans of the stained gels
were made to obtain relative numerical units using a GE Healthcare Image Quant
350. ANOVA was performed to determine statistical differences using GraphPad
Prism 5 on a DELL Latitude E6420 computer using Windows 7 OS.
Immunohistochemistry of mini-pig corneas. One quarter of each cornea was
fixed in 4% paraformaldehyde in phosphate buffer containing 5% sucrose. The
corneas were processed through a sucrose gradient prior to embedding in OCT.
Immunohistochemical staining was conducted using antibodies against cytoker-
atin, CD172a, smooth muscle actin, LYVE-1, CD31, collagen V (Supplementary
Table 11). Corneal sections (7 μm) were fixed in cold 4% PFA followed by ice-cold
methanol, air-dried, washed in PBS and then blocked with 5% normal goat serum
(NGS) in PBS. All primary antibodies were incubated overnight at 4 °C. Slides were
washed in PBS with 1% Tween 20 and then incubated with secondary antibodies
diluted 1:1000 in blocking solution. After washing the slides were dehydrated and
mounted in Vectashield Antifade Mounting Medium with DAPI (Vector Labora-
tories, Burlingame, CA, USA).
Slides stained using lectin were washed in PBS, stained with lectin overnight at
4 °C, washed and counterstained with DAPI, before mounting in Vectashield
Antifade Mounting Medium. Fluorescent images were obtained with a confocal
laser-scanning microscope (LSM800, Carl Zeiss Microscopy, Göttingen, Germany).
Immunohistochemical staining of exosomes was conducted using dual staining
with CD9 and TSG101, per the ISEV positive staining requirement for one
transmembrane protein and one cytosolic protein associated with exosomes.46
Corneal sections were air dried, washed in PBS, and permeabilized in PBS with
0.3% Triton-X. The sections were washed and incubated in Tris-buffered saline
(TBS) containing 50 mM ammonium chloride. The samples were blocked in PBS
with 5% NGS and 0.01 g/mL saponin at room temperature prior to incubation in
primary antibodies overnight. Slides were washed in PBS containing 5% FBS and
0.01 g/mL saponin and incubated in secondary antibodies diluted in blocking at
room temperature. The samples were quenched for autofluorescence using Vector®
TrueVIEW™ Autofluorescence Quenching Kit (Vector Laboratories, Burlingame,
CA, USA). Slides were stained with DAPI (5 μg/mL) for 10 min prior to mounting
in Vectashield Antifade Mounting Medium (Vector Laboratories, Burlingame, CA,
USA). Fluorescent images were obtained with a confocal laser-scanning microscope
(LSM880, Carl Zeiss Microscopy, Göttingen, Germany). Images were denoised
using Zen Blue v2.3. Three-dimensional reconstructions of the slices were
generated in Imaris v9.2.1 (Bitplane Inc., Concord, MA, USA). Surfaces were
reconstructed for Tsg101 using a manual threshold value of 5. A co-localization
channel was constructed for CD9 and Tsg101 and surfaces were reconstructed
using a manual threshold value of 1.5. All surfaces used a minimum voxel
threshold of 10 and surface grain threshold of 0.141 μm.
Immunohistochemistry for LL37 was performed as described above for
exosomes. Three-dimensional reconstructions of the slices were generated in
Imaris v9.2.1 (Bitplane Inc., Concord, MA, USA). Ten 700 μm3 regions of interest
(ROIs), five in the epithelium and five in the stroma, were generated for each slice.
LL37 staining in each ROI was reconstructed as spots with an intensity threshold of
7.57 and a minimum voxel threshold of 10. The number of spots and sum intensity
of each ROI was analyzed by the total volume of the ROIs. A one-way
Kruskal–Wallis test was performed using a Dunn’s multiple comparisons test
(GraphPad Prism v9.0.2, GraphPad Software, LLC., San Diego, CA, USA).
Electron microscopy of mini-pig corneas. The mini-pig corneal/construct sam-
ples were fixed using 2.5% glutaraldehyde/2% paraformaldehyde in 100 mM
cacodylate buffer pH 7.2 at room temperature (RT) for 12 h after dissection and
placed in 100 mM cacodylate storage buffer pH 7.2. The samples were processed
for TEM and SBF-SEM using a method for the generation of high backscatter
electron contrast for serial block face scanning (SBF SEM).47 After the fixation, the
sample quadrants were cut into thin <1 mm slices to preserve the positioning of the
implant in relation to host cornea. Each sample slice was transferred to 1.5%
potassium ferricyanide/1% osmium tetroxide in cacodylate buffer for 1 h and then
washed in distilled water. The samples were then placed sequentially in 1% aqueous
thiocarbohydrazide, 1% osmium tetroxide and 1% aqueous uranyl acetate, each for
1 h. All the staining steps were followed by 30 mins distilled water washing steps.
The samples were then incubated for 1 h in a solution of lead aspartate at 60 °C
and then washed in two changes of distilled water for 30 min. They were
dehydrated in an ethanol series from 70% through to 100% and, following via
propylene oxide infiltration, they were embedded in CY212 (TAAB) epoxy resin
and polymerized for 24 h at 60 °C.
The surfaces of polymerized resin blocks were then trimmed and attached to
Gatan (PEP6590) specimen pins. The pins were gold coated and transferred to a
Zeiss Sigma VP FEG SEM equipped with a Gatan 3View2 system, where datasets of
up to 1000 images were acquired of the block surface every 100 nm through
automated sectioning. Each image was acquired at 4K × 4K pixels, at a pixel
resolution of between 6.5 and 21 nm and a pixel dwell time of 8 μs, using an SEM
accelerating voltage of 3.5 keV in low vacuum variable pressure mode (28–30 Pa).
Imaging data were acquired from a 26.5 μm × 26.5 μm region of interest. Selected
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serial image sequences were extracted from the image data and 3D reconstructions
were generated using Amira 6.1 software (FEI). For TEM, ultrathin 90 nm sections
were taken from the SBF-SEM pins using a Leica UC6 ultramicrotome. The sections
were then collected on TAAB G300HEX grids and examined using a JEOL 1010
TEM at an accelerating voltage of 80Kv.
Statistics and reproducibility. The Alamar Blue proliferation assay of HCEC on
the hydrogels was analyzed using a two-way ANOVA (n=5 technical replicates
(TR) per group). BMDC activation assays were performed using a one-way
ANOVA with a Brown-Forsythe test and Tukey’s multiple comparisons test with a
confidence interval of 95% for each marker (GraphPad Prism 8.4.2, GraphPad
Software, LLC., San Diego, CA, USA). The unit of analysis was the mouse (n=6,
per group).
The unit of analysis for the clinical statistics was the eye. The clinical statistics
were conducted on uneven population sizes (CLP-PEG n=4; CLP-PEG-MPC n=4;
unoperated n=8). For variables with repeated measures over time, a mixed-effects
analysis with Geisser-Greenhouse’s correction was performed (α=0.05) with a
Tukey multiple comparison test for treatment effects by time point (GraphPad
Prism 8.4.2). Post-mortem collagen content analysis was performed using the two-
way ANOVA with Tukey’s multiple comparisons test. (α=0.05) (IMB® SPSS®
Statistics Version 25, IMB Corp., Armonk, NY, USA). Ordinal data for
histopathological assessments of corneal epithelial hyperplasia and
neovascularization were analyzed by Mann–Whitney U. Statistical significance was
set at p≤0.05.
All graphs were prepared using GraphPad Prism v9.0.2. Data are displayed as
mean with individual data points or mean ± standard error of the mean.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The quantitative datasets and full GLP mini-pig report generated during the current
study are available in the Figshare repository (https://doi.org/10.6084/m9.
figshare.14251088.v1)45. The image datasets generated during the current study are
available from the corresponding author on reasonable request.
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